Grillo J A, Gorson K C, Ropper A H, Lewis J, Weinstein R
Division of Neurology, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA 02135, USA.
Neurology. 2001 Nov 13;57(9):1699-701. doi: 10.1212/wnl.57.9.1699.
The safety and efficiency of a novel method of rapid-infusion IV immunoglobulin (IVIg) were retrospectively reviewed in 50 patients with neuromuscular disorders. There were 89 adverse events after 341 rapid infusions (26%), 3.5% of which were considered to be major (requiring hospitalization) and 66% minor. All patients recovered without sequelae, and there were no deaths. Fourteen of 17 patients (82%) receiving maintenance therapy preferred rapid IVIg infusion because of its convenience. Rapid-infusion IVIg can be given safely and conveniently in many patients with neuromuscular disorders.
对50例神经肌肉疾病患者回顾性评估了一种新型快速输注静脉注射免疫球蛋白（IVIg）方法的安全性和有效性。341次快速输注后出现89例不良事件（26%），其中3.5%被认为是严重不良事件（需要住院治疗），66%为轻微不良事件。所有患者均康复且无后遗症，无死亡病例。接受维持治疗的17例患者中有14例（82%）因方便而更倾向于快速输注IVIg。快速输注IVIg对于许多神经肌肉疾病患者而言安全且方便。
